Effect of pioglitazone therapy in lean type1 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 78, Issue 3, 2007, Pages 349-354

  Bhat, R ^a   Bhansali, A ^a   Bhadada, S ^a   Sialy, R ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Double blind trial; Thiazolidinediones; Type1 diabetes

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN METABOLISM; LIPID METABOLISM; MAJOR CLINICAL STUDY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; PLACEBOS; POSTPRANDIAL PERIOD; THIAZOLIDINEDIONES; THINNESS;

EID: 35649024168     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.04.012     Document Type: Article

References (20)

1. The Diabetes Control and Complications Trial Research Group: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med. 329 (1993) 977-986.
2. The Diabetes Control and Complications Trial Research Group: lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial, J. Am. Assoc. 276 (1996) 1409-1415.
3. The Diabetes Control and Complications Trial Research Group: hypoglycemia in the Diabetes Control and Complications Trial, Diabetes 46 (1997) 271-286.
4. DeFronzo R.A., Simonson D., and Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type2 (non-insulindependent) and type1 (insulin-dependent) diabetes mellitus. Diabetologia 23 (1982) 313-319
5. DeFronzo R.A., Hendler R., and Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 31 (1982) 795-801
6. Del Prato S., Nosadini R., Tiengo A., Tessari P., Avogaro A., Trevisan R., et al. Insulin-mediated glucose disposal in type1 diabetes: evidence for insulin resistance. J. Clin. Endocrinol. Metab. 57 (1983) 904-910
7. Mäkimattila S., Virkamäki A., Malmström R., Utriainen T., and Yki-Jarvinen H. Insulin resistance in type1 diabetes mellitus: a major role for reduced glucose extraction. J. Clin. Endocrinol. Metab. 81 (1996) 707-712
8. Purnell J.Q., Dev R.K., Steffes M.W., Cleary P.A., Palmer J.P., Hirsch I.B., et al. Brinzell JD: relationship of family history of type2 diabetes, hypoglycemia and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 52 (2003) 2623-2629
9. DeFronzo R.A. Pharmacologic therapy for type2 diabetes mellitus (Review). Ann. Intern. Med. 131 (1999) 281-303
10. Inzucchi S.E. Oral antihyperglycemic therapy for type2 diabetes: scientific review. J. Am. Med. Assoc. 287 (2002) 360-372
11. Pagano G., Tagliaferro V., Carta Q., Caselle M.T., Bozzo C., Vitelli F., et al. Metformin reduces insulin requirement in type1 (insulin-dependent) diabetes. Diabetologia 24 (1983) 351-354
12. Hamilton J., Cummings E., Zdravkovic V., Finegood D., and Daneman D. Metformin as an adjunct therapy in adolescents with type1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 26 (2003) 138-143
13. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
14. Hirose H., Kawai T., Yamamoto Y., Taniyama M., Tomita M., Matsubara K., et al. Effects of pioglitazone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type2 diabetes. Metabolism 51 (2002) 314-317
15. Sharma P.K., Bhansali A., Sialy R., Malhotra S., and Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type2 diabetes mellitus. Clin. Endocrinol. 65 (2006) 722-728
16. Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Monnier L., Lapinski H., et al. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type2 diabetes patients. Diabetes Care 26 (2003) 881-885
17. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type2 diabetes patients. Diabetes Care 26 (2003) 881-885
18. Strowig S.M., and Raskin P. The effect of Rosiglitazone on overweight subjects with type1 diabetes. Diabetes Care 28 (2005) 1562-1567
19. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med. 115 (2003) 4248S
20. Shim W.S., Do M.Y., Kim S.K., Kim H.J., Hur K.Y., Kang E.S., et al. Long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clin. Endocrinol. 65 (2006) 453-459